Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Beam Therapeutics Inc.

Beam Therapeutics Inc. (BEAM) Stock Overview

Explore Beam Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.

BEAM●NASDAQ
HealthcareBiotechnology
$25.26
$0.31(1.24%)
U.S. Market opens in 12h 9m

Beam Therapeutics Inc. (BEAM)

Meyka AI Score

Z

Key Financials

Market Cap2.6B
P/E Ratio-30.63
EPS (TTM)$-3.29
ROE-0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$26.43
3 Months$38.70
1 Year Target$33.24

BEAM Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Beam Therapeutics Inc. (NASDAQ: BEAM) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Beam Therapeutics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BEAM on the NASDAQ shows an RSI of 43.11, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $33.24 for the NASDAQ listing.

Key metrics behind Beam Therapeutics Inc.'s NASDAQ-traded stock include a P/E ratio of -30.63 and a market capitalization of 2.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BEAM on the NASDAQ.

Price Performance (NASDAQ: BEAM)

1-Day Change
1.24%
5-Day Change
7.90%
1-Month Change
-15.12%
3-Month Change
-28.91%
6-Month Change
2.56%
Year-to-Date (YTD) Change
-8.87%
1-Year Change
3.48%
3-Year Change
1.20%
5-Year Change
-73.40%
All-Time (Max) Change
34.72%

Contact Information

https://www.beamtx.com
857 327 8775
238 Main Street, Cambridge, MA, 02142

Company Facts

5,400 Employees
IPO DateFeb 6, 2020
CountryUS
Actively Trading

Frequently Asked Questions